Biogen and Samsung Bioepis' Byooviz launches in USA

US biotech Biogen (Nasdaq: BIIB) and South Korea’s Samsung Bioepis have announced that Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) has been launched in the USA.

Healthcare provider engagement, promotional activity, collaborations with professional societies and patient advocacy groups have commenced and Byooviz will be commercially available on July 1, 2022, through major distributors across the USA. The list price will be $1,130 per single use vial to administer 0.5mg via intravitreal injection, which the companies say is 40% lower than the current list price of Lucentis, which is marketed in the USA by Roche (ROG: SIX).

The US Food and Drug Administration FDA approved Byooviz in September 2021 for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization.